Shares of Acelyrin (SLRN) are down 62% or $17.35 at $10.55 after the company announced top-line results from Part B of a Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa, or HS. The primary endpoint of HiSCR75 at week 16 did not meet statistical significance. Moonlake Therapeutics (MLTX), which is also developing a treatment for HS, is up 19% at $63.00 on the news.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SLRN:
- Acelyrin (NASDAQ: SLRN) Plummets on Disappointing HS Trial Results
- Acelyrin Inc trading resumes
- Acelyrin announces izokibep trial did not meet primary endpoint
- ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa
- Acelyrin Inc trading halted, news pending